|
Segment reporting (Details) - Schedule of segment reporting information, by segment (USD $)
In Thousands, unless otherwise specified |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jan. 31, 2014
|
Jan. 31, 2013
|
Jan. 31, 2014
|
Jan. 31, 2013
|
|
| Segment Reporting Information [Line Items] | ||||
| Clinical laboratory services | $ 13,848 | $ 13,320 | $ 28,707 | $ 28,497 |
| Product revenues | 8,054 | 7,876 | 15,717 | 16,309 |
| Royalty and license fee income | 1,026 | 1,014 | 2,637 | 3,033 |
| Total revenues | 22,928 | 22,210 | 47,061 | 47,839 |
| Cost of clinical laboratory services | 9,292 | 9,425 | 19,001 | 19,135 |
| Cost of product revenues | 3,865 | 4,143 | 7,712 | 8,327 |
| Research and development | 832 | 968 | 1,649 | 1,979 |
| Selling, general and administrative | 10,084 | 10,892 | 20,612 | 22,308 |
| Provision for uncollectible accounts receivable | 912 | 1,335 | 1,784 | 2,929 |
| Legal | 1,496 | 1,441 | 2,877 | 3,142 |
| Operating income (loss) | (3,553) | (5,994) | (6,574) | (9,981) |
| Other | 15 | 43 | 76 | 56 |
| Foreign currency gain | 20 | 104 | 317 | 333 |
| Share-based compensation | 109 | 160 | 212 | 301 |
|
Clinical Labs [Member] | Cost of Clinical Laboratory Services [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 2 | 2 | 4 | 4 |
|
Clinical Labs [Member] | Selling, General and Administrative Expenses [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 9 | 11 | 19 | 22 |
|
Clinical Labs [Member] | Total [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 11 | 13 | 23 | 26 |
|
Clinical Labs [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Clinical laboratory services | 13,848 | 13,320 | 28,707 | 28,497 |
| Total revenues | 13,848 | 13,320 | 28,707 | 28,497 |
| Cost of clinical laboratory services | 9,292 | 9,425 | 19,001 | 19,135 |
| Research and development | 3 | 86 | 14 | 175 |
| Selling, general and administrative | 4,981 | 4,911 | 10,031 | 9,873 |
| Provision for uncollectible accounts receivable | 920 | 1,213 | 1,764 | 2,769 |
| Legal | 142 | 51 | 290 | 158 |
| Total operating expenses | 15,338 | 15,686 | 31,100 | 32,110 |
| Operating income (loss) | (1,490) | (2,366) | (2,393) | (3,613) |
| Interest | (11) | (13) | (22) | (22) |
| Other | 9 | 17 | 27 | 24 |
| Income (loss) before income taxes | (1,492) | (2,362) | (2,388) | (3,611) |
| Depreciation and amortization included above | 355 | 355 | 710 | 663 |
| Capital expenditures | 103 | 241 | 362 | 420 |
|
Life Sciences [Member] | Research and Development Expense [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 1 | 1 | 1 | |
|
Life Sciences [Member] | Selling, General and Administrative Expenses [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 5 | 6 | 9 | 6 |
|
Life Sciences [Member] | Total [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 5 | 7 | 10 | 7 |
|
Life Sciences [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Product revenues | 8,054 | 7,876 | 15,717 | 16,309 |
| Royalty and license fee income | 1,026 | 1,014 | 2,637 | 3,033 |
| Total revenues | 9,080 | 8,890 | 18,354 | 19,342 |
| Cost of product revenues | 3,865 | 4,143 | 7,712 | 8,327 |
| Research and development | 543 | 570 | 1,069 | 1,175 |
| Selling, general and administrative | 3,318 | 4,081 | 6,813 | 8,353 |
| Provision for uncollectible accounts receivable | (8) | 122 | 20 | 160 |
| Legal | 15 | 31 | 37 | 36 |
| Total operating expenses | 7,733 | 8,947 | 15,651 | 18,051 |
| Operating income (loss) | 1,347 | (57) | 2,703 | 1,291 |
| Interest | 3 | 5 | 8 | 4 |
| Other | (6) | 17 | 21 | 20 |
| Foreign currency gain | 20 | 104 | 317 | 333 |
| Income (loss) before income taxes | 1,364 | 69 | 3,049 | 1,648 |
| Depreciation and amortization included above | 621 | 799 | 1,262 | 1,604 |
| Capital expenditures | 7 | 87 | 82 | 170 |
|
Therapeutics [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Research and development | 286 | 312 | 566 | 629 |
| Total operating expenses | 286 | 312 | 566 | 629 |
| Operating income (loss) | (286) | (312) | (566) | (629) |
| Income (loss) before income taxes | (286) | (312) | (566) | (629) |
| Depreciation and amortization included above | 2 | 7 | 6 | 14 |
|
Other Segments [Member] | Selling, General and Administrative Expenses [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 93 | 140 | 179 | 268 |
|
Other Segments [Member] | Total [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 93 | 140 | 179 | 268 |
|
Other Segments [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Selling, general and administrative | 1,785 | 1,900 | 3,768 | 4,082 |
| Legal | 1,339 | 1,359 | 2,550 | 2,948 |
| Total operating expenses | 3,124 | 3,259 | 6,318 | 7,030 |
| Operating income (loss) | (3,124) | (3,259) | (6,318) | (7,030) |
| Interest | (44) | 1 | (100) | 3 |
| Other | 12 | 9 | 28 | 12 |
| Income (loss) before income taxes | (3,156) | (3,249) | (6,390) | (7,015) |
| Depreciation and amortization included above | 24 | 25 | 49 | 55 |
|
Consolidated [Member] | Cost of Clinical Laboratory Services [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 2 | 2 | 4 | 4 |
|
Consolidated [Member] | Research and Development Expense [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 1 | 1 | 1 | |
|
Consolidated [Member] | Selling, General and Administrative Expenses [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 107 | 157 | 207 | 296 |
|
Consolidated [Member] | Total [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 109 | 160 | 212 | 301 |
|
Consolidated [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Clinical laboratory services | 13,848 | 13,320 | 28,707 | 28,497 |
| Product revenues | 8,054 | 7,876 | 15,717 | 16,309 |
| Royalty and license fee income | 1,026 | 1,014 | 2,637 | 3,033 |
| Total revenues | 22,928 | 22,210 | 47,061 | 47,839 |
| Cost of clinical laboratory services | 9,292 | 9,425 | 19,001 | 19,135 |
| Cost of product revenues | 3,865 | 4,143 | 7,712 | 8,327 |
| Research and development | 832 | 968 | 1,649 | 1,979 |
| Selling, general and administrative | 10,084 | 10,892 | 20,612 | 22,308 |
| Provision for uncollectible accounts receivable | 912 | 1,335 | 1,784 | 2,929 |
| Legal | 1,496 | 1,441 | 2,877 | 3,142 |
| Total operating expenses | 26,481 | 28,204 | 53,635 | 57,820 |
| Operating income (loss) | (3,553) | (5,994) | (6,574) | (9,981) |
| Interest | (52) | (7) | (114) | (15) |
| Other | 15 | 43 | 76 | 56 |
| Foreign currency gain | 20 | 104 | 317 | 333 |
| Income (loss) before income taxes | (3,570) | (5,854) | (6,295) | (9,607) |
| Depreciation and amortization included above | 1,002 | 1,186 | 2,027 | 2,336 |
| Capital expenditures | 110 | 328 | 444 | 590 |
|
Cost of Clinical Laboratory Services [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 2 | 2 | 4 | 5 |
|
Research and Development Expense [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | 1 | 1 | 1 | |
|
Selling, General and Administrative Expenses [Member]
|
||||
| Segment Reporting Information [Line Items] | ||||
| Share-based compensation | $ 107 | $ 157 | $ 207 | $ 295 |